When was T3 Pharma founded?

T3 Pharma was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is T3 Pharma located?

T3 Pharma is headquartered in Basel, Switzerland.

How many employees does T3 Pharma have?

As of Apr 30, 2026, the latest employee count at T3 Pharma is 32.

Is T3 Pharma a funded company?

T3 Pharma is a funded company, having raised a total of $42.7M across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2016.

When was the latest funding round of T3 Pharma?

T3 Pharma's latest funding was a $***** Series C round on Jul 22, 2020, with participation from 3 investors.

Where does T3 Pharma rank among its competitors?

T3 Pharma ranks 790th amongst 3229 active competitors, of which 1114 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of T3 Pharma?

T3 Pharma's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

T3 Pharma - 2026 Company Profile, Team, Funding & Competitors

T3 Pharma is an acquired company based in Basel (Switzerland), founded in 2015 by Simon Ittig, Christoph Kasper, Helmut Kessmann and Marlise Amstutz. It operates as a Developer of novel and innovative medicines to treat cancer. T3 Pharma has raised $42.7M in funding from Boehringer Ingelheim Venture Fund and Wille Finance. The company has 3229 active competitors, including 1114 funded and 765 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of novel and innovative medicines to treat cancer. The company has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviors of live bacteria. The company's lead candidate drug is T3P-Y058-739 for solid tumors.

Website: www.t3pharma.com/
Social
Email ID: *****@t3pharma.com
Part Of

Key Metrics

Founded Year

2015

Location

Basel, Switzerland

Stage

Acquired

Total Funding

$42.7M in 3 rounds

Latest Funding Round

Series C, Jul 22, 2020, $*****

Investors

Boehringer Ingelheim Venture Fund & 4 more

Ranked

790^th among 3229 active competitors

Employee Count

32 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2968 more

Exit Details

Acquired by Boehringer Ingelheim (Nov 22, 2023)

View T3 Pharma's full profile

T3 Pharma got acquired by Boehringer Ingelheim on Nov 22, 2023 at an acquisition amount of $*****.

Click here to take a look at T3 Pharma's acquisition in detail

T3 Pharma has raised a total funding of $42.7M over 3 rounds. Its first funding round was on Jul 01, 2016. Its latest funding round was a Series C round on Jul 22, 2020 for $*****. 3 investors participated in its latest round. T3 Pharma has 5 institutional investors.

Here is the list of recent funding rounds of T3 Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 22, 2020	2943677	Series C	1962826	6177877	9145669	4647189
Sep 26, 2019	3044233	Series B	2955123	7763893	2649785	Reference Capital
Jul 01, 2016	9730545	Grant (prize money)	9669411	8251668	8083926	5053914

Access funding benchmarks and valuations. Sign up today!

View details of T3 Pharma's funding rounds and investors

The founders of T3 Pharma are Simon Ittig, Christoph Kasper, Helmut Kessmann and Marlise Amstutz.

Here are the details of T3 Pharma's key team members:

Simon Ittig: CEO & Co-Founder of T3 Pharma.
Christoph Kasper: CSO & Co-Founder of T3 Pharma.
Helmut Kessmann: Co-Founder of T3 Pharma.
Marlise Amstutz: Co-Founder of T3 Pharma.

View details of T3 Pharma's Founder profiles and Board Members

T3 Pharma's employee count trend

T3 Pharma has 32 employees as of Apr 26. Here is T3 Pharma's employee count trend over the years:

Uncover T3 Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of T3 Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of T3 Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
790th	T3 Pharma 2015, Basel (Switzerland), Acquired	Developer of novel and innovative medicines to treat cancer	$42.7M	Boehringer Ingelheim Venture Fund, BaseLaunch ... & 3 others	45/100